Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
- Conditions
- LeukemiaNon-Hodgkin's LymphomaNHL
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2007-08-14
- Lead Sponsor
- Cambridge Antibody Technology
- Target Recruit Count
- 50
- Registration Number
- NCT00515892
- Locations
- ๐บ๐ธ
Tower Hematology Oncology Medical Group, Beverly Hills, California, United States
๐บ๐ธWarren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
๐ต๐ฑKlinika Hamtologii Uniwersytetu Medycznego (Medical University of Lodz), Lodz, Poland
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
- Conditions
- LeukemiaHairy Cell LeukemiaHCL
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2007-04-18
- Lead Sponsor
- Cambridge Antibody Technology
- Target Recruit Count
- 40
- Registration Number
- NCT00462189
- Locations
- ๐ต๐ฑ
Klinika Hamtologii Uniwersytetu Medycznego (Medical University of Lodz), Lodz, Poland
๐บ๐ธStanford University School of Medicine, Stanford, California, United States
๐ฌ๐งRoyal Marsden Hospital and Institute of Cancer Research, Surrey, United Kingdom
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
- Conditions
- Leukemia
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2007-04-17
- Lead Sponsor
- Cambridge Antibody Technology
- Target Recruit Count
- 50
- Registration Number
- NCT00457860
- Locations
- ๐บ๐ธ
Indiana University Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธTower Hematology Oncology Medical Group, Beverly Hills, California, United States
๐บ๐ธWarren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States